James Greenan-Barrett
jgreenanbarrett.bsky.social
James Greenan-Barrett
@jgreenanbarrett.bsky.social
NIHR Academic Clinical Fellow in Infectious Diseases | Specialist Registrar in Infectious Diseases & General Internal Medicine | UCL Respiratory & LSHTM | Interested in TB biomarkers, disease states & natural history
Reposted by James Greenan-Barrett
Check out our new paper in @lancetmicrobe.bsky.social

In this IPD-MA we show that single-gene transcripts are equivalent to multi-gene signatures to Dx subclinical TB

They perform consistently across settings + show potential clinical utility to stratify therapy

#IDsky #TBsky

bit.ly/47jU7GN
Single-gene transcripts for subclinical tuberculosis: an individual participant data meta-analysis
Single-gene transcripts are equivalent to multi-gene signatures for detection of subclinical tuberculosis, with consistent performance across settings. Single-gene transcripts show potential clinical ...
bit.ly
October 14, 2025 at 11:31 AM
Check out our new paper in @lancetmicrobe.bsky.social

In this IPD-MA we show that single-gene transcripts are equivalent to multi-gene signatures to Dx subclinical TB

They perform consistently across settings + show potential clinical utility to stratify therapy

#IDsky #TBsky

bit.ly/47jU7GN
Single-gene transcripts for subclinical tuberculosis: an individual participant data meta-analysis
Single-gene transcripts are equivalent to multi-gene signatures for detection of subclinical tuberculosis, with consistent performance across settings. Single-gene transcripts show potential clinical ...
bit.ly
October 14, 2025 at 11:31 AM
Reposted by James Greenan-Barrett
Optimising the use of currently available treatments through treatment stratification could reduce treatment duration by 2-months for the majority. TB treatment stratification strategies should be prospectively trialled in a phase III RCT.
#TBSky
June 13, 2025 at 8:25 AM
Reposted by James Greenan-Barrett
We’re hiring! Looking for a laboratory post-doc fellow to help us disentangle protective and pathogenic T cells in TB, so we can stratify disease-risk after infection, and develop more effective vaccines. Interdisciplinary science in the heart of London. What's not to like? More here: bit.ly/4iIEiwu
March 27, 2025 at 10:58 PM
Reposted by James Greenan-Barrett
New preprint (with all pre-print caveats!) tinyurl.com/589ffhu4 on Mtb infection risk by sex & age.
Men are at higher risk of #tuberculosis v women- but unclear how much driven by higher infection vs progression to disease. We meta-analysed Mtb immunoreactivity surveys to find out more🧵 #tbsky
Sex Differences in the Risk of Mycobacterium Tuberculosis Infection: A Systematic Review and Meta-Analysis of Population-Based Immunoreactivity Surveys
Background: Tuberculosis (TB) killed 1·25 million people globally in 2023. Men have a 1·7-fold higher TB incidence than women, but it is not known to what exten
papers.ssrn.com
January 10, 2025 at 8:20 AM
“…despite the recent introduction of BPaL/M, resistance to these new antituberculosis drugs has already developed in at least 27 countries across four continents. Furthermore, a quarter of these cases involved patient-to-patient transmission”

Worrying stuff
January 5, 2025 at 8:27 AM
Reposted by James Greenan-Barrett
Interested in the immunopathology of human tuberculosis? Here is our latest review:
www.science.org/doi/10.1126/...
Immunopathology in human tuberculosis
The balance between protective and pathological immune responses shapes progression of Mycobacterium tuberculosis infection.
www.science.org
December 13, 2024 at 10:59 PM
Reposted by James Greenan-Barrett
🆕️⚡️⚡️Selected TB blood RNA signatures& CRP do not provide biomarkers of microbiological clearance to support TB treatment cessation at 8 weeks
CRP achieved marginal albeit statistically significant discrimination/AUROC 0.69(95%CI 0.52–0.87) #idsky #medsky #tbsky
publications.ersnet.org/content/erj/...
November 21, 2024 at 1:40 PM
Reposted by James Greenan-Barrett
First wave ISGs (eg MX1) induced rapidly, correlate with VL & infectivity - potential biomarker to stratify patients who'll benefit from antivirals?
November 30, 2024 at 2:50 PM
Check out our paper on RNA biomarkers in COVID-19

MX1 expression occurred early in infection before PCR detection…potential role to stratify treatment

#IDSky
December 1, 2024 at 10:21 PM
Historical evidence that mass CXR screening is feasible and effective

Very cool study - lots to be learnt from the past…

#TBSky
DYK in 1957, Glasgow, Scotland ran the largest ever screening campaign against #tuberculosis?

715,000 people (76% of entire adult population) were X-rayed over just 5 weeks!

In a new study, we looked at the long-term impact of this campaign. journals.plos.org/plosmedicine...

#episky #idsky 🧪🛟
November 19, 2024 at 11:21 PM
#UnionConf2024 has wrapped up, and what a conference! Some fascinating talks and great discussions. Seems to me that there are more questions than answers right now in #TBSky but its an exciting time..

Some personal highlights (in no particular order):
1/10
November 18, 2024 at 11:06 AM